Antioxidant and Apoptotic Effect of Edaravone on Cisplatin-Induced Brain Injury in Rats

Area of Science:

• Neuroscience
• Pharmacology
• Toxicology

Background:

• Cisplatin is a widely used chemotherapy agent.
• Cisplatin can induce significant neurotoxicity, including brain damage.
• Preventive strategies against cisplatin-induced brain injury are crucial.

Purpose of the Study:

• To investigate the efficacy of edaravone in preventing cisplatin-induced brain damage.
• To assess the impact of edaravone on oxidative stress markers and brain tissue integrity following cisplatin administration.

Main Methods:

• The study involved 40 female Wistar albino rats divided into four groups: control, cisplatin, edaravone, and cisplatin + edaravone.
• Biochemical analysis of malondialdehyde (MDA) and nitric oxide (NO) levels in blood.
• Immunohistochemical evaluation of brain tissue for damage markers (p53, GFAP, Ki 67).

Main Results:

• Cisplatin administration significantly increased MDA and NO levels and caused substantial brain tissue damage compared to controls.
• Edaravone treatment in combination with cisplatin markedly reduced these elevated markers and tissue damage.
• Statistical analysis confirmed significant differences (p < 0.05) in damage markers and tissue integrity between groups.

Conclusions:

• Edaravone demonstrates a protective effect against cisplatin-induced brain injury.
• The findings suggest edaravone may serve as a viable therapeutic agent for preventing or treating chemotherapy-induced neurotoxicity.
• Further research is warranted to explore clinical applications of edaravone in cancer patients receiving cisplatin.